Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Conditions
Multiple Myeloma
Phase I
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
- Trial withYale University
- Start Date04/12/2022
- End Date08/01/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Adam Boruchov, MD
- Agatha Hecht
- Alexis Walker
- Anamika Katoch, MD
- Andrea Brennan
- Andrea Martelli
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Francesca Montanari, MD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Jaykumar Thumar, MBBS, MD
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Justin Persico, MD
- Katherine Harvey, MD, MPH
- Kelsey Martin, MD
- Kert Sabbath, MD, FACP
- Khanh Nguyen, MD
- Kristen Hoxie
- M. Sung Lee, MD
- Madeline Santiago
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Noffar Bar, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sarah Carlson
- Stephen Lattanzi, MD
- Stuart Seropian, MD
- Su Hsien Lim, MD
- Sudhanshu Mulay, MD
- Syed Bilgrami, MBBS
- Tara Anderson
- Terri Parker, MD
- Victor Chang, MD
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Last Updated06/15/2022
- Study HIC#2000028918